- Home
- KZIA
as of 12-04-2025 3:32pm EST
$13.05
$0.20
-1.51%
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Chart Type:
Time Range:
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 16.6M | IPO Year: | 1999 |
| Target Price: | $16.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $25.40 | Next Earning Date: | 12-26-2025 |
| Revenue: | $1,199,108 | Revenue Growth: | -26.28% |
| Revenue Growth (this year): | -97.21% | Revenue Growth (next year): | -39.00% |
AI-Powered KZIA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.69%
75.69%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
Compare KZIA vs Leading Stocks
See how KZIA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.